LGMN Antibody (monoclonal) (M02)
Mouse monoclonal antibody raised against a partial recombinant LGMN.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| E |
---|---|
Primary Accession | Q99538 |
Other Accession | BC003061 |
Reactivity | Human |
Host | mouse |
Clonality | Monoclonal |
Isotype | IgG1 kappa |
Clone Names | M1 |
Calculated MW | 49411 Da |
Gene ID | 5641 |
---|---|
Other Names | Legumain, Asparaginyl endopeptidase, Protease, cysteine 1, LGMN, PRSC1 |
Target/Specificity | LGMN (AAH03061.1, 1 a.a. ~ 433 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | LGMN Antibody (monoclonal) (M02) is for research use only and not for use in diagnostic or therapeutic procedures. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a cysteine protease that has a strict specificity for hydrolysis of asparaginyl bonds. This enzyme may be involved in the processing of bacterial peptides and endogenous proteins for MHC class II presentation in the lysosomal/endosomal systems. Enzyme activation is triggered by acidic pH and appears to be autocatalytic. Protein expression occurs after monocytes differentiate into dendritic cells. A fully mature, active enzyme is produced following lipopolysaccharide expression in mature dendritic cells. Overexpression of this gene may be associated with the majority of solid tumor types. This gene has a pseudogene on chromosome 13. Several alternatively spliced transcript variants have been described, but the biological validity of only two has been determined. These two variants encode the same isoform.
References
1.Targeting Cell Surface Alpha(v)beta(3,5) Integrins Increases Therapeutic Efficacies of a Legumain Protease-Activated Auristatin Prodrug.Liu Y, Bajjuri KM, Liu C, Sinha SC.Mol Pharm. 2011 Oct 31.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.